よむ、つかう、まなぶ。

MC plus(エムシープラス)は、診療報酬・介護報酬改定関連のニュース、

資料、研修などをパッケージした総合メディアです。


11【参考資料1-6】9価HPVワクチンファクトシート (46 ページ)

公開元URL https://www.mhlw.go.jp/stf/newpage_29181.html
出典情報 厚生科学審議会予防接種・ワクチン分科会(第41回 11/18)《厚生労働省》
低解像度画像をダウンロード

資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。

1912

神経 55:179-183 https://www.jstage.jst.go.jp/article/ans/56/3/56_93/_pdf/-char/ja

1948

1322.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514333/pdf/khvi-4514311-451430

1913

127. Yokota, S., et al. (2018). Human papilloma virus(HPV) vaccination-associated neuro-

1949

6-1012010.pdf

1914

immunopathic syndrome(HANS): a unique symptomatic spectrum and the pathological role

1950

138.

1915

of hypothalamus. ⾃律神経 55(3): 171-178.

1951

effectiveness analysis of prophylactic cervical cancer vaccination in Japanese women.Int J

1916

http://search.jamas.or.jp/link/ui/2019282514

1952

Gynecol Cancer. 2010;20(3):385-92

1917

128. Aratani, S., et al. (2018). What occurs in human papilloma virus vaccination-associated

1953

139.

1918

neuro-immunopathic syndrome(HANS)?: implications of previous animal model studies. ⾃

1954

Introducing HPV vaccine and scaling up screening procedures to prevent deaths from cervical

1919

律神経 55(3): 165-117. http://search.jamas.or.jp/link/ui/2019282513.

1955

cancer in Japan: a cost-effectiveness analysis. Bjog. 2012;119(2):177-86.

1920

129. ⾼嶋 博.(2019).脳炎・脳症・脊髄症の新たな展開 ヒトパピローマウイルスワクチ

1956

140.

1921

ン接種後の神経症状は、なぜ⼼因性疾患と間違われるのか.神経治療学 2018;35:536-542.

1957

Effectiveness Analysis of a Quadrivalent Human Papillomavirus Vaccine (6/11/16/18) for

1922

http://search.jamas.or.jp/link/ui/2019260843

1958

Females in Japan.Value Health Reg Issues. 2013;2(1):92-7.

1923

130. Ushida, T., et al. (2016). The Effect of Guidance regarding Home Exercise and ADL

1959

141.

1924

on Adolescent Females Suffering from Adverse Effects after HPV Vaccination in Japanese

1960

effectiveness of routine and catch-up vaccination of girls and women with a nine-valent HPV

1925

Multidisciplinary Pain Centers. Pain Res Manag 2016: 3689352.

1961

vaccine in Japan: a model-based study. BMC Infect Dis. 2021;21(1):11

1926

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4904598/pdf/PRM3682016-3689352.pdf

1962

142 . Isshiki T. HPV vaccination for cervical cancer prevention is not cost-effective in Japan.

1927

131. WHO (2017). Human papillomavirus vaccines: WHO position paper, May 2017. Wkly

1963

Asian Pac J Cancer Prev. 2014; 15(15): 6177-80.

1928

Epidemiol Rec 92(19): 241-268.

1964

143 . Kitano T. Stopping the HPV vaccine crisis in Japan: Quantifying the benefits and risks

1929

132. Centers for Disease Control and Prevention.(2020). Vaccine for HPV.

1965

of HPV vaccination in quality-adjusted life-years for appropriate decision-making. J Infect

1930

https://www.cdc.gov/hpv/parents/vaccinesafety.html

1966

Chemother. 2020; 26(3): 225-30.

1931

133. Control, E. C. f. D. P. a. (2020). Guidance on HPV vaccination in EU countries: focus

1967

144. 厚⽣労働省. 第 14 回厚⽣科学審議会予防接種・ワクチン分科会予防接種基本⽅針部

1932

on boys, people living with HIV and 9-valent HPV vaccine introduction.

1968

会 資料 3 沈降13価肺炎球菌結合型ワクチンを⾼齢者へ定期接種で使⽤することの是⾮

1933

https://www.ecdc.europa.eu/sites/default/files/documents/Guidance-on-HPV-vaccination

1969

に関する検討⽅針について

1934

-in-EU-countries2020-03-30.pdf

1970

https://www.mhlw.go.jp/file/05-Shingikai-10601000-Daijinkanboukouseikagakuka-

1935

134. Agency, E. M. HPV vaccines: EMA confirms evidence does not support that they cause

1971

Kouseikagakuka/0000111764.pdf

1936

CRPS or POTS 2016.

1972

145. Taguchi, A., et al. (2020). Multistate Markov Model to Predict the Prognosis of High-

1937

http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/HPV_vacc

1973

Risk Human Papillomavirus-Related Cervical Lesions. Cancers (Basel) 12(2).

1938

ines_20/European_Commission_final_decision/WC500196773.pdf

1974

146. 村澤秀樹 ⼤久保⼀郎, 荒川⼀郎. (2014). ⼦宮頸がん検診へのヒトパピローマウイル

1939

135. Zhang, Z., et al. (2017). Expanded strain coverage for a highly successful public health

1975

ス DNA 検査導⼊に関する費⽤対効果分析.⽇本予防医学会雑誌 2014;9 (2):83-91.

1940

tool: Prophylactic 9-valent human papillomavirus vaccine. Hum Vaccin Immunother 13(10):

1976

147. De Vincenzo, R., et al. (2014). Long-term efficacy and safety of human papillomavirus

1941

2280-2291. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5647960/pdf/khvi-5647913-

1977

vaccination. Int J Womens Health 6: 999-1010.

1942

5647910-1346755.pdf

1978

148. Datta, S., et al. (2019). Assessing the cost-effectiveness of HPV vaccination strategies

1943

136. Yang, D. Y. and K. Bracken (2016). Update on the new 9-valent vaccine for human

1979

for adolescent girls and boys in the UK. BMC Infect Dis 19(1): 552.

1944

papillomavirus prevention. Can Fam Physician 62(5): 399-402.

1980

149. Brisson, M., et al. (2016). Health and Economic Impact of Switching from a 4-Valent

1945

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4865336/pdf/0620399.pdf

1981

to a 9-Valent HPV Vaccination Program in the United States. J Natl Cancer Inst 108(1).

1946

137.

Luxembourg, A., et al. (2015). Phase II studies to select the formulation of a

1982

150. Murasawa, H., et al. (2014). Evaluation of health-related quality of life for hypothesized

1947

multivalent HPV L1 virus-like particle (VLP) vaccine. Hum Vaccin Immunother 11(6): 1313-

1983

medical states associated with cervical cancer. Asian Pac J Cancer Prev 15(22): 9679-9685.

91

Konno R, Sasagawa T, Fukuda T, Van Kriekinge G, Demarteau N. (2010).Cost-

Yamamoto N, Mori R, Jacklin P, Osuga Y, Kawana K, Shibuya K, et al.(2012).

Yamabe K, Singhal PK, Abe M, Dasbach EJ, Elbasha EH. (2013).The Cost-

Cody P, Tobe K, Abe M, Elbasha EH.(2012). Public health impact and cost

92